With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent.

With its particular acclaim for sterile injectables, oncology and ophthalmic products, the company has begun to reinforce its position on the international stage by venturing into markets like Saudi Arabia, Singapore, Israel and CIS regions.

With times like these, investors shouldn’t panic and keep a close eye on the fundamentally strong companies,

On Wednesday, the domestic equity markets were driven majorly by events namely the commencement of the IPO of Life Insurance Corporation (LIC) and an increase of 40 bps in repo rate by Monetary Policy Committee (MPC).  

On Thursday, the bulls took the charge and forced the benchmark indices to close on a higher note. The broader markets also replicated the benchmark indices and closed in green.